Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
TL Shigle, VW Handy… - Therapeutic advances in …, 2020 - journals.sagepub.com
Cytomegalovirus (CMV) reactivation is one of the most common infections affecting
allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies …
allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies …
Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells
T Ivana, P Robert, S Pavel, T Lenka, K Irena - Transplant Immunology, 2022 - Elsevier
Herpesviruses can either cause primary infection or may get reactivated after both
hematopoietic cell and solid organ transplantations. In general, viral infections increase post …
hematopoietic cell and solid organ transplantations. In general, viral infections increase post …
Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective …
H Yoshimura, A Satake, Y Ishii, J Ichikawa… - Journal of Infection and …, 2022 - Elsevier
Introduction Cytomegalovirus (CMV) infection is a common complication following
allogeneic hematopoietic stem cell transplantation (aHSCT) and is associated with …
allogeneic hematopoietic stem cell transplantation (aHSCT) and is associated with …
Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation
S Neuber, K Wagner, T Goldner, P Lischka… - Journal of …, 2017 - Am Soc Microbiol
Human cytomegalovirus (HCMV) genome encapsidation requires several essential viral
proteins, among them pUL56, pUL89, and the recently described pUL51, which constitute …
proteins, among them pUL56, pUL89, and the recently described pUL51, which constitute …
Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation
J Maertens, AC Logan, J Jang, G Long… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised
patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti …
patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti …
Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV …
Z Huang, H Yan, Y Teng, W Shi, L Xia - Frontiers in Immunology, 2022 - frontiersin.org
Currently, the graft-versus-host disease (GVHD) prophylaxis consists of an
immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post …
immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post …
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing
S Chou, RJ Ercolani, MK Sahoo… - Antimicrobial agents …, 2014 - Am Soc Microbiol
In immunosuppressed hosts, the development of multidrug resistance complicates the
treatment of cytomegalovirus (CMV) infection. Improved genotypic detection of impending …
treatment of cytomegalovirus (CMV) infection. Improved genotypic detection of impending …
Letermovir for the management of cytomegalovirus infection
LJ Bowman, JI Melaragno… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Cytomegalovirus (CMV) is a major cause of morbidity and mortality in
immunocompromised patients. Available antivirals are fraught with adverse effects and risk …
immunocompromised patients. Available antivirals are fraught with adverse effects and risk …
Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections
P Frange, M Leruez-Ville - Medecine et maladies infectieuses, 2018 - Elsevier
Cytomegalovirus (CMV) infection is a common complication in immunocompromised
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic …
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic …
Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment
K Shiraki, M Takemoto, T Daikoku - Expert review of anti-infective …, 2021 - Taylor & Francis
Introduction: Acyclovir has led to the development of successful systemic therapy for herpes
simplex virus and varicella-zoster virus (VZV) infection, and the use of valacyclovir and …
simplex virus and varicella-zoster virus (VZV) infection, and the use of valacyclovir and …